Loading organizations...

Medyria is a technology company.
Medyria is a Swiss medtech company that develops and commercializes advanced blood flow velocity sensing technology for precise cardiovascular diagnostics. Its core product, the PyCath microcatheter, enables direct measurement of Blood Flow Velocity (BFV). This innovative technology facilitates sophisticated endovascular catheter navigation and sensing, providing medical professionals with enhanced tools for interventional procedures.
Dr. Mauro Sette founded Medyria in 2012, recognizing a critical need for accurate real-time cardiovascular data during interventions. With an MSc in Biomedical Engineering, Dr. Sette applied his specialized background to address blood flow measurement complexities. His insight was to simplify complex procedures by offering precise, data-driven solutions for better clinical outcomes.
The company primarily serves cardiologists and medical professionals requiring high-precision diagnostics to guide treatment. Medyria's long-term vision focuses on transforming cardiovascular interventions by offering technologies that increase patient and physician safety and efficacy. It aims to improve clinical outcomes through more informed diagnostic capabilities.
Medyria has raised $6.0M across 2 funding rounds.
Medyria has raised $6.0M in total across 2 funding rounds.
Medyria has raised $6.0M in total across 2 funding rounds.
Medyria's investors include Verve Ventures, FONGIT, Z%C3%BCrcher%20Kantonalbank.
Medyria is a Swiss medtech company founded in 2012 (or 2013 per some sources) that develops blood flow velocity (BFV) sensing technology for interventional cardiology.[1][2][4] It offers its sensor as an OEM component for integration into other devices and has created PyCath, a standalone microcatheter that measures both pressure and BFV simultaneously to assess coronary physiology, including obstructive and microvascular ischemia in conditions like angina pectoris and coronary artery disease (CAD).[1][3][4][5] Serving cardiologists and healthcare institutions, Medyria addresses unmet needs in real-time coronary and microvascular assessment during catheter-based procedures, reducing procedural risks, time, and costs while improving patient outcomes.[2][5] At Series B-II stage with $10.37M raised (latest $3.98M two years ago), the company shows growth via recent milestones like the March 2025 KENOBI Trial launch and preclinical completion for PyCath.[1][5]
Medyria emerged from market research identifying gaps in real-time coronary and microvascular assessment, leading to its unique BFV sensing technology protected by four patent families in Europe, China, Japan, and the US.[2] Founded in Winterthur, Switzerland, by Dr. Mauro Sette (a biomedical and cardiac engineering expert), the company started in 2012-2013 with a lean team of about six combining over 50 years in engineering, clinical research, and business development.[1][2][5] Early traction included OEM sensor sales and development of devices like PhysioCath (an all-in-one angiography tool), followed by PyCath as the flagship for full heart physiology evaluation.[2][4][5] Pivotal moments: securing CHF 1.5M and CHF 3.7M funding rounds, completing preclinical PyCath work, a first-in-human trial with 40 patients in Germany, and OEM agreements.[5]
Medyria rides the wave of precision cardiology amid rising CAD and angina prevalence, where traditional angiography misses microvascular issues affecting ~50% of patients—its BFV tech expands eligibility to 100% by completing microvascular assessment.[5] Timing aligns with post-pandemic demand for efficient, minimally invasive procedures and regulatory pushes for advanced diagnostics (e.g., FDA Fast Track analogs in medtech).[1] Favorable market forces include aging populations, medtech funding resurgence in Europe/Switzerland's innovation hubs like Technopark Winterthur, and OEM demand for sensor tech in cardiovascular devices.[2][5] It influences the ecosystem by enabling partners to build BFV-enabled tools, potentially standardizing real-time flow metrics in cath labs and accelerating adoption of integrated ischemia diagnostics.[1][3]
Medyria's PyCath positions it for clinical adoption and market entry post-KENOBI Trial results, with topline data potentially by late 2025 driving regulatory milestones and partnerships.[1][5] Trends like AI-enhanced cath lab tools and microvascular-focused therapies will amplify its edge, while global expansion (e.g., via Portuguese branch) and further funding could scale OEM/standalone sales.[4][5] Its influence may grow by redefining cardiology workflows, tying back to its core strength: transforming incomplete coronary studies into full physiological insights for better patient care.[1][2]
Medyria has raised $6.0M across 2 funding rounds. Most recently, it raised $4.0M Series B in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $4.0M Series B | Verve Ventures | |
| Jan 1, 2015 | $2.0M Series A | FONGIT | Verve Ventures, Z%C3%BCrcher%20Kantonalbank |